Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 2/20 | 0.31 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | ASGR1 | P07306 | 1/20 | 0.30 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21630478 | 1.00 | FFAR1 (0.41) | FFAR1USP30BACE1BACE2PIK3R1 | |
| SCHEMBL29339875 | 0.92 | FFAR1 (0.41) | FFAR1USP30BACE1BACE2PIK3R1 | |
| SCHEMBL31009816 | 0.92 | FFAR1 (0.41) | FFAR1USP30BACE1BACE2PIK3R1 | |
| SCHEMBL22086042 | 0.81 | USP30 (0.44) | FFAR1USP30DGAT1HSD11B1PRMT5 | |
| SCHEMBL659798 | 0.80 | CHRM2 (0.44) | FFAR1USP30BACE1BACE2HSD11B1 | |
| SCHEMBL29548160 | 0.80 | CHRM2 (0.44) | FFAR1USP30BACE1BACE2HSD11B1 | |
| SCHEMBL26702696 | 0.80 | CHRM2 (0.44) | FFAR1USP30BACE1BACE2HSD11B1 | |
| SCHEMBL15273003 | 0.80 | USP30 (0.47) | FFAR1USP30BACE1BACE2DDB1 | |
| SCHEMBL660078 | 0.79 | USP30 (0.49) | FFAR1USP30BACE1BACE2DGAT1 | |
| SCHEMBL30796575 | 0.79 | FFAR1 (0.41) | FFAR1USP30BACE1BACE2DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360140-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2024-10-31 | — | — | US | disclosed |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-05-05 | — | — | US | disclosed |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | FFAR1 227/4885USP30 3917/4885BACE1 1452/4885 |
| US-20240360140-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | FFAR1 227/4885USP30 3917/4885BACE1 1452/4885 |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | FFAR1 227/4885USP30 3917/4885BACE1 1452/4885 |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | FFAR1 227/4885USP30 3917/4885BACE1 1452/4885 |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | FFAR1 227/4885USP30 3917/4885BACE1 1452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.